Evidence map›Paper›PMID 40366558›Full record

ArticleMolecular neurobiology2025

Chronic Hyponatremia Potentiates Innate Anxiety-Like Behaviors Through the Dysfunction of Monoaminergic Neurons in Mice.

Haruki Fujisawa, Nobuhiko Magara, Shogo Nakayama, Sachiho Fuse, Naoko Iwata, Masaya Hasegawa, Hisayoshi Kubota, Hirotaka Shoji, Satoko Hattori, Hideo Hagihara and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Haruki Fujisawa *Department of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan. hfuji@fujita-hu.ac.jp.
Nobuhiko Magara *Department of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Shogo NakayamaDepartment of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Sachiho FuseDepartment of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Naoko IwataDepartment of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Masaya HasegawaDepartment of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Medical Science, Toyoake, Aichi, 470-1192, Japan.
Hisayoshi KubotaDepartment of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Medical Science, Toyoake, Aichi, 470-1192, Japan.
Hirotaka ShojiDivision of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Aichi, 470‑1192, Japan.
Satoko HattoriDivision of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Aichi, 470‑1192, Japan.
Hideo HagiharaDivision of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Aichi, 470‑1192, Japan.
Hidetsugu FujigakiDepartment of Advanced Diagnostic System Development, Fujita Health University Graduate School of Medical Sciences, Toyoake, Aichi, 470-1192, Japan.
Yusuke SeinoDepartment of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Akihiro MouriDepartment of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Medical Science, Toyoake, Aichi, 470-1192, Japan.
Tsuyoshi MiyakawaDivision of Systems Medical Science, Center for Medical Science, Fujita Health University, Toyoake, Aichi, 470‑1192, Japan.
Toshitaka NabeshimaLaboratory of Health and Medical Science Innovation (HMSI), Fujita Health University Graduate School of Medical Science, Toyoake, Aichi, 470-1192, Japan.
Atsushi SuzukiDepartment of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan.
Yoshihisa SugimuraDepartment of Endocrinology, Diabetes and Metabolism, School of Medicine, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-Cho, Toyoake, Aichi, 470-1192, Japan. sugiyosi@fujita-hu.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyponatremia is the most common clinical electrolyte disorder. Once thought to be asymptomatic in response to adaptation by the brain, recent evidence suggests that chronic hyponatremia (CHN) may induce neurological manifestations, including psychological symptoms. However, the specific psychological symptoms induced by CHN, the mechanisms underlying these symptoms, and their potential reversibility remain unclear. Therefore, this study aimed to determine whether monoaminergic neurotransmission is associated with innate anxiety-like behaviors potentiated by CHN in a mouse model of CHN secondary to the syndrome of inappropriate antidiuresis. In the present study, using a mouse model of the syndrome of inappropriate antidiuresis presenting with CHN, we showed that the sustained reduction of serum sodium ion concentrations potentiated innate anxiety-like behaviors in the light/dark transition and open field tests. We also found that serotonin and dopamine levels in the amygdala were significantly lower in mice with CHN than in controls. Additionally, phosphorylation of extracellular signal-regulated kinase (ERK) in the amygdala was significantly reduced in mice with CHN. Notably, after correcting for CHN, the increased innate anxiety-like behaviors, decreased serotonin and dopamine levels, and reduced phosphorylation of ERK in the amygdala were normalized. These findings further underscore the importance of treating CHN and highlight potential therapeutic strategies for alleviating anxiety in patients with CHN, which will improve their quality of life.

Indexed as

AnxietyBehavior, AnimalBiogenic MonoaminesHyponatremiaNeuronsAmygdalaAnimalsChronic DiseaseDopamineExtracellular Signal-Regulated MAP KinasesMaleMiceMice, Inbred C57BLPhosphorylationSerotoninBiogenic MonoaminesDopamineExtracellular Signal-Regulated MAP KinasesSerotoninAmygdala,AnxietyDopamineERKHyponatremiaSerotonin

Identifiers

PMID40366558

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.